P325Statin inhibits synthesis of type I collagen in patients with rheumatic heart disease

Herry, Yan

doi:10.1093/cvr/cvy060.240

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hydroxychloroquine has long been used in the treatment of autoimmune diseases such as rheumatoid arthritis, Sjögren's syndrome and systemic lupus erythematosus and was shown to limit the dysregulated IL-1β-GM-CSF axis in peripheral blood mononuclear cells from a cohort of Australian Aboriginal patients with ARF [59]. The use of statins to inhibit collagen synthesis and slow the fibrotic processes in rheumatic valvular lesions has also been recently investigated as a potential pharmacological treatment for RHD [164].…”

Section: Secondary Preventionmentioning

confidence: 99%

Rheumatic heart disease: A review of the current status of global research activity

Dooley

Ahmad

Pandey

et al. 2021

Autoimmunity Reviews

View full text Add to dashboard Cite

Section: Secondary Preventionmentioning

confidence: 99%

Rheumatic heart disease: A review of the current status of global research activity

Dooley

Ahmad

Pandey

et al. 2021

Autoimmunity Reviews

View full text Add to dashboard Cite

“…Previous studies have tried several drugs to inhibit fibrosis. However, the results are inconsistent, and these drugs have not yet become standard therapy [ 26 , 27 , 28 ]. Therefore, new approaches and treatments are needed to prevent RHD progression, and perhaps to improve LA function.…”

Section: Introductionmentioning

confidence: 99%

Effect of Dapagliflozin on Patients with Rheumatic Heart Disease Mitral Stenosis

Asrial,

Reviono,

Soetrisno

et al. 2023

JCM

View full text Add to dashboard Cite

(1) Background: Mitral stenosis is the most common rheumatic heart disease (RHD). Inflammation and fibrosis are the primary pathophysiology, resulting in left atrial stress and dysfunction. Dapagliflozin is a new heart failure treatment with anti-inflammation and anti-fibrosis effects from previous studies. However, the specific role of dapagliflozin in RHD mitral stenosis is unknown. This study aims to investigate (i) the effect of dapagliflozin on biomarkers of fibrosis, NT-pro BNP levels and left atrial function; (ii) the relationship between the changes in fibrosis biomarkers with left atrial function and NT-pro BNP levels. (2) Methods: An open-label randomized study was conducted on 33 RHD mitral stenosis patients divided into a dapagliflozin group which received 10 mg dapagliflozin and standard therapy, and a control group which only received standard therapy. All patients were examined for levels of PICP, MMP-1/TIMP-1 ratio, TGF-β1, NT-proBNP, mitral valve mean pressure gradient (MPG), and net atrioventricular compliance (Cn) pre- and post-intervention. (3) Results: This study found a significant increase in PICP and TGF-β1 and a reduction in the MMP-1/TIMP-1 ratio in the dapagliflozin group and the control group (p < 0.05). In the dapagliflozin group, the levels of NT-pro BNP decreased significantly (p = 0.000), with a delta of decreased NT-pro BNP levels also significantly greater in the dapagliflozin group compared to the control (p = 0.034). There was a significant increase in Cn values in the dapagliflozin group (p = 0.017), whereas there was a decrease in the control group (p = 0.379). Delta of changes in Cn values between the dapagliflozin and control groups also showed a significant value (p = 0.049). The decreased MPG values of the mitral valve were found in both the dapagliflozin and control groups, with the decrease in MPG significantly greater in the dapagliflozin group (p = 0.031). There was no significant correlation between changes in the value of fibrosis biomarkers with Cn and NT-pro BNP (p > 0.05). (4) Conclusions: This study implies that the addition of dapagliflozin to standard therapy for RHD mitral stenosis patients provides benefits, as evidenced by an increase in net atrioventricular compliance and decreases in the MPG value of the mitral valve and NT-pro BNP levels (p < 0.05). This improvement was not directly related to changes in fibrosis biomarkers, as these biomarkers showed ongoing fibrosis even with dapagliflozin administration.

show abstract

P325Statin inhibits synthesis of type I collagen in patients with rheumatic heart disease

Cited by 2 publications

References 0 publications

Rheumatic heart disease: A review of the current status of global research activity

Rheumatic heart disease: A review of the current status of global research activity

Effect of Dapagliflozin on Patients with Rheumatic Heart Disease Mitral Stenosis

Contact Info

Product

Resources

About